Clinical Trial

A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa

Name: A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa — clinical trial record (NCT07547813)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The main purpose of this study is to evaluate the effect of LAD328 compared to placebo in participants with moderate-to-severe Hidradenitis Suppurativa (HS), and to access the safety, tolerability, pharmacokinetic and immunogenicity in participants with moderate-to-severe HS.

Trial Details

NCT Number	NCT07547813
Lead Sponsor	Almirall, S.A.
Conditions	Hidradenitis Suppurativa
Enrollment	50 participants
Start Date	2026-04
Primary Completion	2027-02 (estimated)
Study Completion	2027-04 (estimated)
Updated on ClinicalTrials.gov	2026-04-23